Download Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020 Report

The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new oncology treatments has provided a major incentive for the pharmaceutical industry to pursue the development of new agents for the treatment of cancer. To tackle the ever rising global cancer burden, the cancer treatment is inclining towards the targeted drug therapy due to the numerous drawbacks associated with conventional chemotherapy. Targeted drug therapy includes targeting various signaling pathways associated to the tyrosine kinase receptors. Ample of studies have been performed which confirm their intrinsic involvement of tyrosine related pathways in development of the tumors.

Until the late 1980s, it was thought of as impossible to target protein kinases by the tractable drugs, the reason lied in the presumed need to compete with adenosine triphosphate (ATP) as well as concerns regarding selectivity of the potential drugs. Since then, considerable progress has been made, and the past few years have seen a number of kinase inhibitors which have entered the market.

Till now, 518 protein kinases have been encoded from the human genome; we call it as Human Kinome. From the encoded human genome, 90 kinases belong to the group of tyrosine kinases. The tyrosine kinase group consists of approximately 30 families, for example the VEGFR family and the fibroblast growth factor receptor (FGFR) family. Six other groups have been identified whose kinases primarily phosphorylate serine and threonine residues.

Tyrosine kinases play the most critical part in the modulation of growth factor signaling. Activated forms of these enzymes can cause increases in tumor cell proliferation and growth, induce antiapoptotic effects, and promote angiogenesis and metastasis. In addition to activation by growth factors, protein kinase activation by somatic mutation is a common mechanism of tumor genesis. Because all of these effects are initiated by receptor tyrosine kinase activation, they are key targets for inhibitors.

The TKI drug discovery has evolved dramatically in recent years. Along with the launch of new drugs, efficient approaches for the development of potent and selective inhibitors with desirable properties have become established. At present kinase inhibitors are being designed from crystallography to deal with different binding modes and unexpected inhibitor induced conformational rearrangements. Much of kinase inhibitors which are supposed to enter in market in near future are rationally designed through high throughput screening and empirical optimization on the basis of structure–activity relationships. Sophisticated proteomic approaches have been developed in conjunction with panels of enzyme assays to allow for a more thorough annotation of kinase inhibitor selectivity.

Now with the considerable amount of research and advancement in technology, kinase signaling pathway is seen as the largest class of potential drug targets by the pharmaceutical industry. Over the last decades, billions have been spent and huge efforts have been taken in basic and clinical cancer research. About a decade ago, the race between drugs and cancer cells reached a new level by introduction of tyrosine kinase inhibitors into pharmacological anti-cancer therapy.

Clinical pipeline of cancer tyrosine kinase inhibitor therapeutics is quite strong due to which competitive product is expected to enter continuously in global market. Owing to increasing cancer incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase inhibitor therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic.

“Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020” Report Highlights:
Introduction to Cancer Tyrosine Kinase Inhibitors
Signaling Pathway of Receptor Tyrosine Kinase
Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
Global Tyrosine Kinase Inhibitors Market Overview
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline: 411 Drugs
Majority of Cancer Tyrosine Kinase Inhibitors in Preclinical Phase: 164 Drugs
Marketed Cancer Tyrosine Kinase Inhibitors: 32 Drugs

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Cancer-Tyrosine-Kinase-Inhibitors-Market-&-Clinical-Pipeline-Outlook-2020.php

1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors

2. Tyrosine Kinase: An Overview

3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies

4. Types of Tyrosine Kinase Receptors
4.1 Epidermal Growth Factor Receptor
4.1.1 Types of Epidermal Growth Factor Receptor
4.1.2 Epidermal Growth Factor Receptor & Ligands
4.1.3 Epidermal Growth Factor Receptor & Cancers

4.2 Platelet-Derived Growth Factor Receptor (PDGFR)
4.2.1 Types of Platelet-Derived Growth Factor Receptor
4.2.2 Platelet-Derived Growth Factor Receptor & Ligands
4.2.3 Platelet-Derived Growth Factor Receptor & Cancer

4.3 Insulin-Like Growth Factor 1 Receptor (IGF-1R)
4.3.1 Insulin-Like Growth Factor 1 Receptor & its Ligands
4.3.2 Insulin-Like Growth Factor 1 Receptor & its role in Cancer

5. Signaling Pathway of Receptor Tyrosine Kinase
5.1 PI3K/Akt Pathway
5.2 Ras/Raf/ERK1/2 Pathway
5.3 The JAK/STAT Pathway

6. Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer

7. BCR-ABL Tyrosine Kinase Inhibitors
7.1 Imatinib
7.2 Nilotinib
7.3 Dasatinib
7.4 Ponatinib
7.5 Bosutinib

8. Epidermal Growth Factor Receptor Kinase Inhibitors Tyrosine
8.1 Gefitinib
8.2 Erlotinib
8. 3 Lapatinib
8.4 Icotinib
8.5 Canertinib
8.6 Afatinib
8.7 Neratinib
8.8 Poziotinib

9. Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
9.1 Sunitinib
9.2 Sorafenib
9.3 Vandetanib
9.4 Pazopanib
9.5 Axitinib
9.6 Cediranib

10. Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
10.1 Role of Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
10.2 Mitigation of Chronic Myeloid Leukaemia
10.3 Role of tyrosine Kinase Inhibitors in Combating Colorectal Cancer
10.4 Gastrointestinal Cancer & Tyrosine Kinase Inhibitor
10.5 Tyrosine Kinase Inhibitor in Breast Cancer

11. Global Tyrosine Kinase Inhibitors Market Overview
11.1 Current Market Scenario
11.2 Cancer Tyrosine Kinase Inhibitors Pipeline Overview

12. Global Tyrosine Kinase Inhibitor Market Dynamics
12.1 Favorable Driving Factors
12.1.1 Research & Development
12.1.2 Strong Clinical Pipeline
12.1.3 Increasing Disease Incidences
12.1.4 Unmet Requirement of Completely Curative Agents
12.1.5 Advancement in Manufacturing Capabilities of the Biopharmaceutical Companies

12.2 Challenges Countered by Tyrosine Kinase Inhibitor Market
12.2.1 Strict Regulatory Guidelines for Approval of Prospective Drug
12.2.2 Long Phase of Research & Development
12.2.3 Funding of Clinical Trials
12.2.4 Highly Competitive Market

13. Global Tyrosine Kinase Inhibitor Market Future Prospects

14. Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Cancer Tyrosine Kinase Inhibitors Clinical Insight by Brand Name, Company & Indication
15.1 Blood Cancer
15.1.1 Ibrutinib (Imbruvica)
15.1.2 Ponatinib (Iclusig)
15.1.3 Dasatinib (Tasigna)
15.1.4 Nilotinib (Tasigna)
15.1.5 Bosutinib (Bosulif)
15.1.6 Radotinib (Supect)

15.2 Breast Cancer
15.2.1 Trastuzumab Subcutaneous (Herceptin SC)
15.2.2 Pertuzumab (Omnitarg & Perjeta)
15.2.3 Lapatinib (Tykerb & Tyverb)
15.2.4 Trastuzumab Biosimilar (CANMAb & Hertraz)
15.2.5 Trastuzumab Biosimilar (Vivitra)

15.3 Gastric Cancer
15.3.1 Apatinib

15.4 Non-small cell lung cancer
15.4.1 Afatinib (Gilotrif, Giotrif & Tomtovok)
15.4.2 Nintedanib (Ofev & Vargatef)
15.4.3 Ceritinib (Zykadia)
15.4.4 Crizotinib (Xalkori)
15.4.5 Icotinib (Conmana)
15.4.6 Gefitinib (Iressa)
15.4.7 Alectinib (Alecensa)

15.5 Renal Cancer
15.5.1 Axitinib (Inlyta)

15.6 Thyroid Cancer
15.6.1 Vandetanib (Caprelsa, Zactima & Zictifa)

15.7 Multiple
15.7.1 Sunitinib (Sutent)
15.7.2 Lenvatinib (Lenvima)
15.7.3 Regorafenib (Stivarga)
15.7.4 Imatinib (Gleevec, Glivec & Ruvise)
15.7.5 Trastuzumab (Herceptin)
15.7.6 Erlotinib (Tarceva)
15.7.7 Ramucirumab (Cyramza)
15.7.8 Cabozantinib (COMETRIQ, Cabometyx & Cometriq)
15.7.9 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM,
Theraloc & VECTHIX)
15.7.10 Sorafenib (Nexavar)
15.7.11 Imatinib (Imatib)

16. Discontinued & Suspended Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company & Phase
16.1 No Development Reported
16.2 Discontinued
16.3 Suspended

17. Competitive Landscape
17.1 AB Science
17.2 Advenchen Laboratories
17.3 Array BioPharma
17.4 ARIAD Pharmaceuticals
17.5 Astellas Pharma (OSI Pharmaceuticals)
17.6 AstraZeneca
17.7 Bayer HealthCare
17.8 Biocad
17.9 Biocon
17.10 Boehringer Ingelheim
17.11 Bristol-Myers Squibb
17.12 Celera Genomics Group
17.13 Celgene Corporation (Avila Therapeutics)
17.14 Celltrion
17.15 Chugai Pharmaceutical
17.16 Cytopia Research
17.17 Daiichi Sankyo (Ambit Biosciences Corporation)
17.18 Dyax
17.19 Eisai Co Ltd
17.20 Exelixis
17.21 GlaxoSmithKline
17.22 Hanmi Pharmaceutical
17.23 Novartis
17.24 Onyx Pharmaceuticals
17.25 Pfizer
17.26 Plexxikon
17.27 Reliance Life Sciences
17.28 Roche
17.29 Shire
17.30 Synthon
17.31 Wyeth
17.32 Xcovery
17.33 Zydus Cadila

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.